CJC-1295 + Ipamorelin (ipamorelina): dosis, protocolo y ciclos, guía completa
Revisado médicamente por el equipo clínico de BHRC — Beverly Hills Rejuvenation Center · Redactado por Sam Brooks · Versión en español: noviembre de…
GHK-Cu: dosis, protocolo de inyección, reconstitución y ciclos (guía 2026)
GHK-Cu: dosis, protocolo de inyección, reconstitución y ciclos (guía 2026) Revisado médicamente por el equipo clínico de BHRC — Beverly Hills Rejuvenation Center ·…
5-Amino-1MQ: para que serve, dosagem e protocolo
BHRC · Pesquisa metabólica e peptídeos · 5-Amino-1MQ Por Jamie Walston · Atualizado em novembro de 2026 · Beverly Hills Rejuvenation Center · Revisado…
DSIP & Sleep Peptides — Dosage Claims vs. the Actual Evidence
Every human DSIP trial was intravenous; every product sold is subcutaneous, a route with no human data. The FDA’s advisory committee declined to recommend it in July 2026. Plus what genuinely works for sleep.
BPC-157 Oral vs. Injected — What the Evidence Actually Supports
No pharmacokinetic study in any species has measured oral BPC-157 absorption. Fewer than 30 humans have taken it. The full regulatory picture including what the April 2026 Category 2 removal did and did not change.
IV Drip Therapy & NAD+ Infusions — What They Do, and What They Don’t
IV drip therapy at BHRC Summerlin from $149. The one controlled Myers’ Cocktail trial and its negative result, the compounding and sterility issue, the G6PD risk, and what the FTC has already enforced against.
Peptides for Skin & Hair: GHK-Cu, Topical Claims and What Actually Has Evidence
Why topical peptides are cosmetics and what that means for their claims, where GHK-Cu really stands, and the only two FDA-approved treatments for androgenetic alopecia — with the label safety language most sites skip.
Hexarelin, GHRP-2 & GHRP-6 — Doses Used in Humans and What the Evidence Shows
The real human endocrinology on GHRP-2, GHRP-6 and hexarelin: doses studied, the cortisol and prolactin problem, tachyphylaxis at sixteen weeks, and why none has a lawful compounding pathway.
Peptides for Weight Loss — The Complete 2026 Guide to What’s Approved and What Isn’t
Oral semaglutide and orforglipron are now approved; retatrutide is not. The compounded GLP-1 window has closed. Plus honest evidence for AOD-9604, tesamorelin, 5-Amino-1MQ and MOTS-c.
NAD+ vs. NMN vs. NR: Dosage, Absorption & What the Human Evidence Supports
NMN’s FDA status was resolved in 2025. NR has the most replicated data. IV NAD+ has almost no outcome evidence. An honest, fully-cited comparison of all three from BHRC.
The “Glow Protocol” (GHK-Cu + BPC-157 + TB-500): What the Evidence Actually Shows
GHK-Cu, BPC-157 and TB-500 reviewed honestly — what each is, what has actually been studied, and why no defensible dosing guide exists.
Tirzepatide vs. Semaglutide vs. Retatrutide — Dosing, Cost & Results Compared
The only head-to-head trial, the full dosing schedules, retatrutide’s real status, and why you cannot compare these trials directly.
Peptide Stacking Guide: Which Peptides Can Be Combined Safely
What is actually known about combining peptides — the regulatory reality, why simultaneous starts are a mistake, and the handling that does matter.
Thymosin Alpha-1 Dosage Guide: Immune Protocol & Reconstitution
Thymosin alpha-1 doses from published clinical studies, its exact US regulatory status, and how reconstitution and syringe math actually work.
Sermorelin Dosage Guide: Protocol, Timing & Results Timeline
Sermorelin protocols from the published trials, why timing matters, a realistic results timeline, and the FDA history most articles get wrong.
